Samsung Bioepis

Today, we announced the initiation of the first-in-human Phase 1 clinical trial of our novel antibody-drug conjugate (ADC) candidate. This significant milestone marks our expansion from biosimilars into novel therapies. Read the press release: bit.ly/4tEPa3E

For 30 years, one scientific principle has been key to driving biosimilar development: comparability. Discover the impact of comparability on the biopharmaceutical industry in our latest issue of Re:Access. shorturl.at/VUvjs

Following Pharma USA 2026 by @RE_Pharma, Thomas Newcomer, our Senior VP and Head of US Commercial, said in an interview that limited employer involvement and formulary decisions hinder biosimilar adoption. A biosimilar-first approach is key. shorturl.at/c4jya

We are conducting a company-wide training program, the AI Academy, from April to July 2026 to cultivate internal AI experts. Having a dedicated AI task force will ensure Samsung Bioepis’ ability to harness the growing power of GenAI.

Like healthcare, building trust in biosimilars requires rigorous science, regulatory standards and global collaboration. By working “together for health,” we strengthen confidence in biosimilars and change patients’ lives. #WorldHealthDay #StandWithScience

To all the healthcare professionals working so tirelessly, especially behind the scenes, to provide care and improve patients’ lives, thank you. We are proud to support your work by expanding access to high-quality biosimilars. #WorldHealthWorkerWeek #WHWWeek

Thomas Newcomer, our Senior VP and Head of US Commercial, highlights how biosimilar competition delivers significant cost savings and expands opportunities for innovative biotech R&D. See the complete keynote address at @RE_Pharma USA 2026: bit.ly/4sMvpat

What challenges and opportunities lie ahead for the US biosimilar market? Watch Thomas Newcomer, our Senior VP and Head of US Commercial, unpack the rapidly evolving US biosimilar market in his keynote speech at @RE_Pharma USA 2026. bit.ly/4szhXq7

Samsung Bioepis was recently featured by Biosimilar Review & Report as the newest addition to their Manufacturer Profiles. Check out the full profile to see how we are expanding access to life-changing biologic treatments. 🔗 shorturl.at/JMmE2

Check the latest on #BiosimilarsExplained where we introduce Switching — the transition from a reference biologic to a biosimilar, expanding patient access while maintaining established standards of care through proven safety, efficacy and quality.

Our partnership with Sandoz is expanding to improve access to life-changing medicines through a new global agreement covering up to five biosimilars currently under development at Samsung Bioepis. Read more: shorturl.at/A6hlX

At Pharma USA 2026, Thomas Newcomer, our Senior VP and Head of US Commercial, emphasized that factors beyond price are critical when evaluating biosimilars. We appreciate the opportunity to drive an insightful discussion on fostering a more robust biosimilar market in the US.

We are pleased to announce a new research collaboration with G2GBIO. In partnership with Epis NexLab, we will co-develop two novel assets utilizing G2GBIO’s proprietary microsphere platform. 🔗 shorturl.at/vG7zs

In an interview with @PharmaScrip, our VP and Innovation Project Lead, Yun Cheol Kim, discusses our long-term goal of becoming a fully integrated biopharmaceutical company with end-to-end capabilities. 🔗Scrip subscribers can read more here: shorturl.at/UcotR

Your environment affects your kidney health.​ As we mark 20 years of World Kidney Day, let’s remember that chronic kidney disease impacts 1 in 10 people worldwide and is increasingly linked to rising temperatures and declining air quality.​ #WorldKidneyDay #OurPlanetOurKidneys

During #PatientSafetyAwarenessWeek, let’s reflect on how the transparent, data-driven process behind biosimilars, from development to post-approval evidence collection, fosters trust and enables informed choices by healthcare professionals and patients.

Europe has significantly advanced biosimilars over the past 20 years. But closing the global access gap requires more than regional leadership. Explore why greater regulatory alignment worldwide is key to closing the gap in our March newsletter. shorturl.at/z8JXU

This #InternationalWomensDay, we celebrate the women at Samsung Bioepis who give their time and expertise to drive progress toward more equitable healthcare and expand access to high-quality biosimilars. #GivetoGain #IWD2026

Jieun Shin, our EVP and Head of the Manufacturing Division, discusses how diversity drives innovation with @AsiaBioSpectrum. We are proud to cultivate a workplace that supports diverse leadership. 🔗Read the full interview here: shorturl.at/rYnAi

The first biosimilar we launched treats various autoimmune diseases. Today, we have three more for the same therapeutic area in our portfolio. We are committed to expanding treatment options and access for patients with autoimmune diseases. #AutoimmuneAwarenessMonth